Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates

Kumar Oberoi, Honey; Garralda Cabanas, Elena

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Kumar Oberoi, Honey
dc.contributor.author	Garralda Cabanas, Elena
dc.date.accessioned	2022-06-28T10:40:27Z
dc.date.available	2022-06-28T10:40:27Z
dc.date.issued	2021-08-15
dc.identifier.citation	Oberoi HK, Garralda E. Unmasking new promises: expanding the antigen landscape for antibody drug conjugates. Clin Cancer Res. 2021 Aug 15;27(16):4459–61.
dc.identifier.issn	1557-3265
dc.identifier.uri	https://hdl.handle.net/11351/7740
dc.description	Antibody–Drug Conjugates; Cancer treatment
dc.description.abstract	Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile
dc.language.iso	eng
dc.publisher	American Association for Cancer Research
dc.relation.ispartofseries	Clinical Cancer Research;27(16)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Càncer - Tractament
dc.subject	Medicaments - Alliberament retardat
dc.subject	Anticossos monoclonals - Ús terapèutic
dc.subject.mesh	Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Prodrugs
dc.subject.mesh	Immunoconjugates
dc.title	Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1158/1078-0432.CCR-21-1353
dc.subject.decs	neoplasias
dc.subject.decs	/farmacoterapia
dc.subject.decs	profármacos
dc.subject.decs	inmunoconjugados
dc.relation.publishversion	https://doi.org/10.1158/1078-0432.CCR-21-1353
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	34135020
dc.identifier.wos	000753846600001
dc.rights.accessrights	info:eu-repo/semantics/openAccess